S&P 500   3,752.47 (-1.76%)
DOW   30,784.83 (-1.55%)
QQQ   302.30 (-2.22%)
AAPL   119.47 (-2.12%)
MSFT   225.59 (-0.87%)
FB   255.44 (+0.01%)
GOOGL   2,031.24 (+0.99%)
TSLA   608.00 (-6.92%)
AMZN   2,961.01 (-1.46%)
NVDA   488.69 (-4.59%)
BABA   229.82 (-2.73%)
CGC   30.70 (-7.64%)
GE   13.32 (-0.89%)
MU   83.07 (-6.78%)
NIO   38.54 (-7.20%)
AMD   77.52 (-4.13%)
T   28.81 (+0.31%)
F   11.76 (-3.37%)
ACB   9.65 (-7.74%)
DIS   185.28 (-3.63%)
BA   221.65 (-3.02%)
NFLX   511.77 (-1.71%)
PFE   34.00 (-1.13%)
S&P 500   3,752.47 (-1.76%)
DOW   30,784.83 (-1.55%)
QQQ   302.30 (-2.22%)
AAPL   119.47 (-2.12%)
MSFT   225.59 (-0.87%)
FB   255.44 (+0.01%)
GOOGL   2,031.24 (+0.99%)
TSLA   608.00 (-6.92%)
AMZN   2,961.01 (-1.46%)
NVDA   488.69 (-4.59%)
BABA   229.82 (-2.73%)
CGC   30.70 (-7.64%)
GE   13.32 (-0.89%)
MU   83.07 (-6.78%)
NIO   38.54 (-7.20%)
AMD   77.52 (-4.13%)
T   28.81 (+0.31%)
F   11.76 (-3.37%)
ACB   9.65 (-7.74%)
DIS   185.28 (-3.63%)
BA   221.65 (-3.02%)
NFLX   511.77 (-1.71%)
PFE   34.00 (-1.13%)
S&P 500   3,752.47 (-1.76%)
DOW   30,784.83 (-1.55%)
QQQ   302.30 (-2.22%)
AAPL   119.47 (-2.12%)
MSFT   225.59 (-0.87%)
FB   255.44 (+0.01%)
GOOGL   2,031.24 (+0.99%)
TSLA   608.00 (-6.92%)
AMZN   2,961.01 (-1.46%)
NVDA   488.69 (-4.59%)
BABA   229.82 (-2.73%)
CGC   30.70 (-7.64%)
GE   13.32 (-0.89%)
MU   83.07 (-6.78%)
NIO   38.54 (-7.20%)
AMD   77.52 (-4.13%)
T   28.81 (+0.31%)
F   11.76 (-3.37%)
ACB   9.65 (-7.74%)
DIS   185.28 (-3.63%)
BA   221.65 (-3.02%)
NFLX   511.77 (-1.71%)
PFE   34.00 (-1.13%)
S&P 500   3,752.47 (-1.76%)
DOW   30,784.83 (-1.55%)
QQQ   302.30 (-2.22%)
AAPL   119.47 (-2.12%)
MSFT   225.59 (-0.87%)
FB   255.44 (+0.01%)
GOOGL   2,031.24 (+0.99%)
TSLA   608.00 (-6.92%)
AMZN   2,961.01 (-1.46%)
NVDA   488.69 (-4.59%)
BABA   229.82 (-2.73%)
CGC   30.70 (-7.64%)
GE   13.32 (-0.89%)
MU   83.07 (-6.78%)
NIO   38.54 (-7.20%)
AMD   77.52 (-4.13%)
T   28.81 (+0.31%)
F   11.76 (-3.37%)
ACB   9.65 (-7.74%)
DIS   185.28 (-3.63%)
BA   221.65 (-3.02%)
NFLX   511.77 (-1.71%)
PFE   34.00 (-1.13%)
Log in
NASDAQ:OGI

OrganiGram Stock Forecast, Price & News

Followed 146 Times   Searched 771 Times  
$2.70
-0.36 (-11.76 %)
(As of 03/4/2021 02:09 PM ET)
Add
Compare
Today's Range
$2.63
Now: $2.70▼
$3.07
50-Day Range
$1.58
MA: $2.67▼
$6.00
52-Week Range
$1.01
Now: $2.70▼
$6.45
Volume685,389 shs
Average Volume29.05 million shs
Market Capitalization$627.13 million
P/E RatioN/A
Dividend YieldN/A
Beta0.3
Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers cannabis flowers, extracts, edibles and oils, beverages, and other cannabis products for adult recreational market under the Edison Reserve, Edison Cannabis Co., ANKR Organics, and Trailblazer brands; and medical cannabis products, including strains, cannabis oils, extracts, edibles, beverages, and vaporizers for the medical market. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.
OrganiGram logo

Headlines

Meme Status Aside, Organigram Stock Is Well Worth the Gamble - InvestorPlace
March 4, 2021 |  investorplace.com
Organigram Launches SHRED Tropic Thunder Jar of J's (Jar of Joints) and Trailblazer SNAX Milk Chocolate Bars - Business Wire
March 3, 2021 |  businesswire.com
Cannabis and Psychedelics are Booming: CEO’s of Sundial Growers, Icanic Brands, OrganiGram, and Delic Holdings Are Ready - Yahoo Finance
March 3, 2021 |  finance.yahoo.com
Why Investors Should Avoid OrganiGram - InvestorPlace
March 2, 2021 |  investorplace.com
Organigram Launches SHRED Tropic Thunder Jar of J’s (Jar of Joints) and Trailblazer SNAX Milk Chocolate Bars - Yahoo Finance
March 2, 2021 |  finance.yahoo.com
Organigram Launches SHRED Tropic Thunder Jar of J’s (Jar of Joints) and Trailblazer SNAX Milk Chocolate Bars
March 2, 2021 |  finance.yahoo.com
Cannabis and Psychedelics are Booming: CEO's of Sundial Growers, Icanic Brands, OrganiGram, and Delic Holdings Are Ready - GlobeNewswire
March 1, 2021 |  globenewswire.com
OrganiGram (OGI) Dips More Than Broader Markets: What You Should Know - Yahoo Finance
February 26, 2021 |  finance.yahoo.com
5 Pot Stocks Money Managers Bought Hand Over Fist in Q4
February 24, 2021 |  finance.yahoo.com
OrganiGram’s Latest Director Appointment Deserves Closer Scrutiny - InvestorPlace
February 22, 2021 |  investorplace.com
How to Buy OrganiGram (OGI) Stock Right Now • Benzinga - Benzinga
February 17, 2021 |  benzinga.com
Steer Clear of These 3 Cannabis Stocks
February 17, 2021 |  stocknews.com
Sales Growth Provides Confidence to OrganiGram Shareholders - InvestorPlace
February 16, 2021 |  investorplace.com
OrganiGram Holdings: Why We Favor A Short-Term Trade Over A Long-Term Hold - Seeking Alpha
February 12, 2021 |  seekingalpha.com
Why Sundial Growers Stock Gained Again, but Tilray and OrganiGram Holdings Dropped Today - Motley Fool
February 11, 2021 |  fool.com
OrganiGram: Reefer Madness Will Come To An End - Seeking Alpha
February 11, 2021 |  seekingalpha.com
Why Sundial Growers Stock Gained Again, but Tilray and OrganiGram Holdings Dropped Today
February 11, 2021 |  finance.yahoo.com
Forget Sundial Growers: These Penny Stocks Are Much Better Buys - The Motley Fool
February 10, 2021 |  fool.com
The Next Four Years Could Be Huge For US CBD Companies
February 10, 2021 |  marketwatch.com
Sundial Growers: The 209% Gain No One Saw Coming - The Motley Fool
February 9, 2021 |  fool.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OGI
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.organigram.ca
Phone1-855-961-9420
Employees516
Year FoundedN/A

Debt

Debt-to-Equity Ratio0.17
Current Ratio2.66
Quick Ratio3.39

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$64.61 million
Price / Sales9.71
Cash Flow$0.03 per share
Price / Cash Flow101.50
Book Value$1.04 per share
Price / Book2.60

Profitability

EPS (Most Recent Fiscal Year)($0.08)
Net Income$-101,290,000.00
Net Margins-207.26%
Return on Equity-10.00%
Return on Assets-7.14%

Miscellaneous

Outstanding Shares232,271,000
Market Cap$627.13 million
Next Earnings Date4/13/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

1.18 out of 5 stars

Medical Sector

872nd out of 1,968 stocks

Pharmaceutical Preparations Industry

424th out of 772 stocks

Analyst Opinion: 2.2Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$2.70
-0.36 (-11.76 %)
(As of 03/4/2021 02:09 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OGI News and Ratings via Email

Sign-up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











OrganiGram (NASDAQ:OGI) Frequently Asked Questions

Is OrganiGram a buy right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last twelve months. There are currently 8 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" OrganiGram stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OGI, but not buy additional shares or sell existing shares.
View analyst ratings for OrganiGram or view top-rated stocks.

What stocks does MarketBeat like better than OrganiGram?

Wall Street analysts have given OrganiGram a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OrganiGram wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting OrganiGram?

OrganiGram saw a increase in short interest in February. As of February 12th, there was short interest totaling 11,430,000 shares, an increase of 36.9% from the January 28th total of 8,350,000 shares. Based on an average daily volume of 21,710,000 shares, the days-to-cover ratio is presently 0.5 days. Approximately 5.0% of the company's shares are short sold.
View OrganiGram's Short Interest.

When is OrganiGram's next earnings date?

OrganiGram is scheduled to release its next quarterly earnings announcement on Tuesday, April 13th 2021.
View our earnings forecast for OrganiGram.

How were OrganiGram's earnings last quarter?

OrganiGram Holdings Inc. (NASDAQ:OGI) released its earnings results on Monday, January, 11th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.14. The business earned $14.69 million during the quarter, compared to analysts' expectations of $16.02 million. OrganiGram had a negative trailing twelve-month return on equity of 10.00% and a negative net margin of 207.26%.
View OrganiGram's earnings history.

How has OrganiGram's stock been impacted by Coronavirus (COVID-19)?

OrganiGram's stock was trading at $1.72 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, OGI stock has increased by 60.5% and is now trading at $2.76.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for OGI?

12 brokerages have issued 12 month target prices for OrganiGram's stock. Their forecasts range from $1.72 to $4.25. On average, they anticipate OrganiGram's stock price to reach $2.93 in the next year. This suggests a possible upside of 6.2% from the stock's current price.
View analysts' price targets for OrganiGram or view top-rated stocks among Wall Street analysts.

Who are OrganiGram's key executives?

OrganiGram's management team includes the following people:
  • Mr. Gregory Engel, CEO & Director (Age 56)
  • Mr. Derrick W. West CPA, CPA, (CA), Chief Financial Officer (Age 54)
  • Mr. Matt Rogers, Sr. VP of Operations
  • Ms. Helen Martin, Sr. VP of Strategic & Legal Affairs and Company Sec. (Age 43)
  • Mr. Paolo De Luca C.A., C.F.A, Chief Strategy Officer (Age 48)
  • Amy Schwalm, VP of Investor Relations
  • Mr. Timothy Emberg, Sr. VP of Sales & Commercial Operations
  • Mr. James Cavanagh, Chief of Staff
  • Mr. Larry Rogers, VP of International Bus. Devel.
  • Mr. Peter R. Hanson, Director of Fin.

Who are some of OrganiGram's key competitors?

Some companies that are related to OrganiGram include Amicus Therapeutics (FOLD), Taro Pharmaceutical Industries (TARO), Intra-Cellular Therapies (ITCI), Global Blood Therapeutics (GBT), CytoDyn (CYDY), Axsome Therapeutics (AXSM), Prelude Therapeutics (PRLD), Xencor (XNCR), Deciphera Pharmaceuticals (DCPH), IGM Biosciences (IGMS), Ligand Pharmaceuticals (LGND), Arcus Biosciences (RCUS), Amarin (AMRN), Morphic (MORF) and Generation Bio (GBIO).
View all of OGI's competitors.

What other stocks do shareholders of OrganiGram own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include KushCo (KSHB), (CGC), Auxly Cannabis Group (CBWTF), The Supreme Cannabis (SPRWF), Medical Marijuana (MJNA), Cannabics Pharmaceuticals (CNBX), MariMed (MRMD), Aurora Cannabis (ACB), EVIO (EVIO) and Gran Tierra Energy (GTE).

What is OrganiGram's stock symbol?

OrganiGram trades on the NASDAQ under the ticker symbol "OGI."

Who are OrganiGram's major shareholders?

OrganiGram's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include ETF Managers Group LLC (8.48%), Renaissance Technologies LLC (0.76%), Penserra Capital Management LLC (0.27%), Swiss National Bank (0.22%), AdvisorShares Investments LLC (0.13%) and Vontobel Holding Ltd. (0.11%).

Which major investors are selling OrganiGram stock?

OGI stock was sold by a variety of institutional investors in the last quarter, including AdvisorShares Investments LLC, and Ancora Advisors LLC.

Which major investors are buying OrganiGram stock?

OGI stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, ETF Managers Group LLC, Penserra Capital Management LLC, Vontobel Holding Ltd., Apollon Wealth Management LLC, Swiss National Bank, Meitav Dash Investments Ltd., and Credit Suisse AG.

How do I buy shares of OrganiGram?

Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OrganiGram's stock price today?

One share of OGI stock can currently be purchased for approximately $2.76.

How much money does OrganiGram make?

OrganiGram has a market capitalization of $641.07 million and generates $64.61 million in revenue each year. The company earns $-101,290,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis.

How many employees does OrganiGram have?

OrganiGram employs 516 workers across the globe.

What is OrganiGram's official website?

The official website for OrganiGram is www.organigram.ca.

Where are OrganiGram's headquarters?

OrganiGram is headquartered at 35 English Dr., Moncton Z4, E1E 3X3.

How can I contact OrganiGram?

OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at 1-855-961-9420.


This page was last updated on 3/4/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.